Introduction
Over the past several decades, an appreciation for the importance of cell and tissue mechanics in cancer initiation, progression, and metastasis has emerged [14, 94, 118, 123, 132, 134] . The protumorigenic cell and tissue mechanophenotype manifests as both an intrinsic alteration of cell and tissue structure and mechanics and changes in the biophysical properties of the tumor microenvironment (i.e., mechanics, geometry, and topology of the extracellular matrix) [82, 97, 105] . In particular, the noncellular extracellular matrix (ECM) component of the tumor microenvironment plays a critical role in promoting invasion and metastasis [11] . What is now emerging is that interactions between the cell and its associated ECM create a dynamic mechanical relationship mediated by a balance of the cell's contractility and the physical state (i.e., elastic vs rigid) of the ECM microenvironment. This biophysical equilibrium serves to regulate a variety of critical cellular processes, including cell differentiation, proliferation, and motility. Not surprisingly, perturbation in the biophysical dynamics between the epithelium and the ECM potentiates the activity of key signaling pathways that regulate tumor growth, invasion, and survival [88] . Interestingly, many of the signaling pathways that promote the aggressive behavior of cancer cells also regulate glucose uptake and glycolysis. Deregulated cellular energetics is an emerging hallmark of aggressive cancers and reflects the metabolic reprogramming event that has been closely linked to tumor cell proliferation, under the hostile conditions of the tumor microenvironment [13, 50] . In this review, we provide a brief overview of the independent roles played by an altered tissue metabolism and an aberrant, stiffened ECM in cancer initiation and progression and highlight emerging data suggesting a regulatory connection between these two critical cancer regulators. We argue that novel tractable biomarkers and efficacious prevention and therapy programs may be developed by targeting the reciprocal feedback loop between cancer metabolism and the aberrant, mechanically modified ECM.
Altered ECM dynamics, increased collagen cross-linking, and mechanical signaling in the tumor microenvironment
ECM stiffening as a hallmark of cancer
Tumors are typically fibrotic and are often characterized by increased and abnormal deposition, turnover, and posttranslational modifications of the ECM that progressively stiffen the stroma [25, 84, 87, 96] . Accordingly, the architecture and physical properties of tumorassociated ECM are fundamentally different from those of the normal tissue stroma. In particular, collagens are often deposited in greater abundance early during cancer development [19, 25, 68, 122, 155] and are major contributors to the tissue stiffness that stimulate mechanosignaling in stromal fibroblasts and the cancerous epithelium [84, 113, 121] . The extracellular processing of collagen is mediated through cleavage of collagen propeptides by specific proteinases. Thereafter, enzymes such as lysyl oxidases and lysyl hydroxylases catalyze covalent intermolecular cross-links between collagens and elastin, modifying their elasticity and tensile strength, profoundly changing various cellular behaviors. The collagen fibers surrounding the normal epithelial structures of soft tissues, such as the mammary gland and lung, are typically curly and anisotropic [25] . For example, in the breast, collagen I levels are tightly regulated with oriented type I collagen fibers hugging in parallel the epithelial tubules and relaxed nonoriented fibrils surrounding the terminal ductal lobular regions. By contrast, transformed epithelial tissue is characterized by an abundance of highly linearized type I collagen bundles that are often oriented perpendicular to the bulk of the noninvading tumor epithelial mass, and along which tumor cells can be seen migrating on thick fibers projecting into the parenchyma [58, 84, 113] . Consistently, malignancy is linked to the expression of ECM remodeling enzymes, including heparanases, 6-O-sulfatases, cysteine cathepsins, and matrix metalloproteases [56, 69] . Breast tumors, as well as head and neck cancer, also show elevated levels of collagen-processing enzymes, including lysyl oxidases and lysyl hydroxylases, and chronic activation of lysyl oxidase, which is a poor prognostic marker [4, 78] . Elevated lysyl oxidasemediated cross-linking also stiffens the tissue ECM through collagen fiber stabilization and enhancement of the mechanical properties, leading to invasion, metastasis, and poor patient survival [4, 27, 84] . As a result of this altered architecture and deregulated remodeling, tumor stroma is typically stiffer than normal stroma. Indeed, the ECM associated with some breast cancer tissue is robustly stiffer than normal [84, 87, 112] . Interestingly, collagen architecture has also been linked with the reduction in breast cancer risk associated with early-age pregnancy [90] . Despite an increased abundance of collagen I in parous stroma, the matrix is actually less linearized and associated with a decrease in tissue stiffness. These aspects of extracellular collagen processing serve to inhibit the invasive phenotype, despite elevated deposition.
Tumor progression is linked to a dynamic and reciprocal remodeling of the local ECM by the resident cancer cells, stromal fibroblasts, and infiltrating endothelium and immune cells [88] . For instance, a local stiffening of the ECM stimulates actomyosin cell contractility, which, through elevated localized traction forces, simultaneously modifies the adjacent ECM and promotes cell growth, invasion, and survival by fostering focal adhesion maturation and enhancing growth factor receptor and G-protein-coupled receptor signaling [21, 99] . Indeed, the increased tumor cell and fibroblast contractility initiates tensiondependent matrix remodeling and promotes the linearization of collagen fibrils surrounding the invasive front of the tumor. In addition to influencing tissue mechanics, these linearized collagen fibrils also facilitate tumor cell invasion and metastasis. For example, migrating transformed mammary epithelial cells have been observed traveling along these linear bundles of collagen [58, 114, 152] . Consistently, stiffening the ECM in vitro and in vivo promotes the malignant progression of oncogenically modified, premalignant mammary epithelial cells [84] . Furthermore, inhibiting tissue fibrosis and stiffening by preventing collagen cross-linking enhanced the latency of tumor formation in Her2/ Neu mice and significantly reduced tumor incidence and grade [84] . Inhibition of lysyl oxidase activity has also been shown to suppress tumor cell metastasis and can modulate the phenotypic characteristics of basal cells [110] . Clearly, altered ECM dynamics are not merely a feature of the tumor microenvironment, but actively contribute to tumor cell aggressiveness.
Because altered ECM dynamics are a fundamental characteristic of cancer, new approaches that exploit these aberrations are of great clinical value. Tumor-associated collagen signatures (TACSs) aim to define the procession of changes with respect to collagen that have been observed and classified as markers of mammary carcinoma progression. TACS-1, when mammary tumors exhibit a localized increase in the deposition of collagen near the tumor lesion, occurs very early in tumor formation. As tumors increase in size, the collagen fibers align parallel to the tumor boundary straight and are denoted TACS-2. The highest risk signature, TACS-3, occurs when collagen fibers are bundled and aligned perpendicular to the tumor border. This signature has the highest stiffness and predicts poor survival in women with invasive breast cancer. In preclinical models and human breast cancer, when TACS-3 is present, breast cancer cells preferentially invade along the stiff collagen fibers into the adjacent stroma, with TACS-3 collagen fibers identifying focal sites of breast cancer cell microinvasion [90, 125, 126] . These studies highlight the clinical importance of altered ECM dynamics in defining and understanding cancer aggressiveness.
Mechanosignaling and cellular tension drive cancer aggressiveness
Cells sense and convert exogenous forces into signaling pathways through a mechanism termed mechanotransduction [48] . Through mechanotransduction, cancer cells respond to mechanical changes in their microenvironment, including increased compression, hydrostatic pressure, shear stress, and elevated ECM stiffness or cell-cell tension. Whereas tissue compression and shear stress are tissue-level forces, the increased ECM stiffness that cancer cells and their associated stromal cells experience begins at the nanoscale and progresses to the tissue level to gradually promote malignant transformation [84, 112] . A shift in the amount or composition of the ECM, an increase in the level of cross-linked matrix, or the reorientation of matrix fibrils cooperate to stiffen the tumor tissue, thereby enhancing the activity of key signaling pathways that stimulate cell growth and survival and promote invasion and migration [96, 106, 115] .
Cells sense, process, and respond to mechanical and other biophysical cues from the ECM using a complex web of systems that include specialized mechanosensitive ion channels and adhesion receptors (e.g., integrins) and their associated adhesion plaque proteins, which propagate signals deep into the cell through an interconnected cytoskeletal-molecular motor network. This orchestrated system allows cells to modulate their shape and nuclear architecture and tune their actomyosin-generated cellular tension that ultimately remodels their local ECM [7, 41, 57, 61, 67, 81] . The best understood matrix-directed mechanotransduction mechanism is initiated through ECM-dependent integrin activation and clustering, resulting in talin recruitment, and through vinculin activation promotes focal adhesion assembly, focal adhesion kinase (FAK) and paxillin phosphorylation, subsequent Rho-ROCK-dependent actin remodeling, and reciprocal actomyosin-mediated cell contractility (Fig. 1a) [37,106,114, In compliant 3D gels with material properties similar to those measured in the normal mammary gland, nonmalignant human mammary epithelial cells form growth-arrested, polarized acini analogous to the terminal ductal lobular units observed at the end buds of the differentiated breast. Incremental stiffening of the basement membrane gel progressively compromises tissue morphogenesis and alters epidermal growth factor-dependent growth of these cells. Thus, colony size progressively increases, lumen formation is compromised, cell-cell junctions are disrupted, and tissue polarity is inhibited. Arrows indicate loss of endogenous basement membrane and disruption of basal polarity. (c) Nonmalignant human epithelial cells grown on stiff substrates show greater cell contractility, measured via traction force microscopy, compared to the same cells grown on softer substrates. Reprinted from [106] by permission of the publisher. 121 ]. Focal adhesions thereafter collaborate with G-protein-coupled receptors and transmembrane receptor tyrosine kinases to enhance cell growth, survival, migration, and invasion through ERK, JNK, and phosphoinositide 3-kinase (PI3K) signaling (Fig. 1b) [84, 106, 151] . In particular, PI3K regulates cell growth, invasion, and survival and has been implicated in tumor aggression and treatment resistance [39, 40] . Not surprisingly, ECM stiffness and elevated epithelial mechanosignaling enhance growth factor receptor-dependent PI3K signaling to foster malignant cell behavior [96] .
The phosphatase and tensin homolog (PTEN) protein, a tumor suppressor frequently altered in human cancers, is the master negative regulator of the PI3K signaling pathway, and therefore plays a critical role in cell growth, proliferation, and survival [51, 80, 89] . Not surprisingly, even a modest reduction in PTEN is sufficient to permit the malignant transformation of a tissue and can accelerate tumor progression and treatment resistance [2] . Indeed, the exquisite cellular sensitivity to PTEN levels and function is reflected by the diverse regulatory mechanisms controlling its expression. For instance, although normal human mammary cells express high levels of PTEN protein, nonmalignant mammary epithelial cells (MECs) propagated in vitro on conventional tissue culture plastic express low levels of PTEN. However, PTEN protein expression is restored and presumably stabilized when MECs are grown within a three-dimensional reconstituted basement membrane (3D rBM) to assemble the "differentiated" acini observed in normal breast tissue in vivo [32, 86] . Intriguingly, the elastic modulus of tissue culture substrates is superphysiologic, whereas the material properties of rBM hydrogels are remarkably similar to those of the normal human breast [63, 106] . Indeed, the ECM within a human breast tumor is stiffer than normal tissue, implying that matrix compliance may stabilize PTEN protein. Consistently, we recently showed that a stiff ECM increases levels of miR-18a, which directly targets PTEN mRNA, both directly and indirectly, by decreasing levels of HOXA9, to regulate malignant transformation and tumor metastasis in culture and in vivo by increasing PI3K/AKT signaling [96] . These findings highlight a direct relationship between PTEN, the biophysical properties of the ECM, and PI3K-dependent malignancy.
Compared to their nonmalignant counterparts, transformed epithelial cells show striking differences in their mechanoresponsiveness that we and others showed can facilitate their growth, invasion, and survival in response to the increased stiffness found in primary tumors [106, 138, 147] . Many tumor cells exhibit differential intermediate filament profiles and cytoskeletal architectures that modify their migratory behavior. The replacement of a keratin-based cytoskeleton with a vimentin-based cytoskeleton is a hallmark of epithelial-tomesenchymal transition (EMT) in mammary tissue and contributes significantly to invasive potential [74, 103, 150] . Cancer cells are also frequently highly contractile and this elevated cytoskeletal tension contributes to their ability to grow, invade, and survive in the hostile tumor microenvironment. For instance, transformed cells plated on compliant substrates spread rapidly, grow, and survive, whereas their normal counterparts do not [147] . Tumor cells also generate high traction forces that disrupt cell-cell junctions, compromise tissue polarity, promote anchorage-independent survival, and enhance invasion (Fig. 1c) [106] . High cellular tension also increases Rho/ROCK activity, which, via engagement of its downstream effectors, promotes tumor cell proliferation, migration, and survival [121] . These findings demonstrate the reciprocal relationship between ECM micromechanical signals and cell structural control, how these signals propagate through signal transduction networks, and the subsequent modulation of key behaviors connected with tumorigenesis, invasion, and metastasis.
Experimental methods to evaluate ECM stiffness and tissue mechanics
The degree of tumor stiffness, which is typically determined by measuring its elastic modulus, has been exploited as a means to detect malignant lesions in an otherwise normal tissue. The elastic modulus is a measure of how easily a material deforms and is calculated by dividing stress by strain; the greater the elastic modulus, the stiffer the material. Thus, the elastic modulus offers a quantitative method for determining mechanical differences between tissues.
Multiple techniques have been utilized to characterize tissue level changes in elastic modulus in tumors with varying degrees of success. Unconfined compression and shear rheology testing have both been used to quantify incremental stiffening of the mammary gland as it transitions from normal to premalignant to invasive cancer, and have demonstrated that the stromal tissue adjacent to the invading epithelium is substantially stiffer than normal [84, 106] . Shear rheology testing has also been used to monitor changes in tissue stiffness during the progression of liver fibrosis [38, 108] . These techniques lend themselves to gross tissue level assays in which resolution and sensitivity are less demanding. However, recent findings that stress the functional implications of ECM stiffness and an altered cell tension on transformation potential and treatment response demand more precise measurements. Thus, although unconfined compression and shear rheology provide valuable quantitative measurements of tissue elastic modulus, they are limited by their millimeter resolution capabilities.
Atomic force microscopy (AFM) is one imaging modality that permits higher resolution imaging of tissue elastic modulus. AFM measures the interaction force between a sample surface, such as a living cell, and a microscale to nanoscale spring-like cantilever. Tipsample interactions generate a force that deflects the cantilever, which can then be optically tracked via a photodiode and converted to an interaction force using the spring constant of the cantilever. The force measurement capability of AFM has been used to measure the regional tissue elastic modulus of cultured brain slices [26] , pancreatic ductal adenocarcinoma tissue [102] , and excised mammary tissue [87, 90, 96, 110] . These measurements yielded high-resolution force heat maps that demonstrate the existence of stiffness tracts that register with regions of collagen fiber enlargement and linearization. Although AFM has effectively characterized changes in tissue elastic modulus at the microscale, the clinical applicability of the technique is severely limited by the requirement of unprocessed samples.
Over the past decade, elastography, which can employ either ultrasound or magnetic resonance imaging (MRI) techniques, has been utilized clinically to map tissue elastic modulus. This technique has found utility in tumor diagnosis [70] , as well as intraoperative localization of tumor tissue during resection of gliomas [127, 141] . Despite its widespread usage, elastography is limited by its low resolution compared with the length scales relevant to many diseases (hundreds of micrometers for ultrasound elastography and millimeters for MRI elastography), the long acquisition times associated with MRI elastography, and issues with tissue penetrance and user variability with ultrasound elastography. Because of the limitations described above, new imaging techniques must be developed to measure tissue elastic modulus as a means of precisely and accurately diagnosing and monitoring cancer.
Metabolism of cancer

Oncogenesis and glycolysis
Transformed cells exhibit aberrant growth rates that demand elevated levels of ATP to support the biogenesis of the cells' four major macromolecules: carbohydrates, proteins, lipids, and nucleic acids. The physician scientist Otto Warburg hypothesized early on that tumor cells must adjust their metabolic machinery to accommodate these energy requirements. Warburg found that tumor cells transition from the conventional ATP-producing system, oxidative phosphorylation (OXPHOS), to glycolysis in the presence of adequate oxygen. The oddity of this observation, known as the Warburg Effect or aerobic glycolysis, is that glycolysis is usually reserved for anaerobic ATP production and, per unit of glucose, is a much less efficient producer of ATP than OXPHOS [148, 149] . Although apparently counterintuitive, glycolysis allows much faster, on-demand, ATP production than OXPHOS, but at the demand of more glucose uptake. Despite having major implications in basic tumor cell biology as well as clinical diagnostics and therapy, tumor metabolism was largely ignored for decades until recently, when transforming oncogenes were found to have both direct and indirect effects on the cell's central metabolism.
At present a growing number of oncogenes and tumor suppressor genes have been functionally linked to cell metabolism (for an excellent comprehensive review, see [13] ). Ras and Src were the first oncogenes associated with the Warburg Effect owing to their induction of glucose transporter (GLUT genes) expression [30] . Similarly PI3K/AKT upregulation leads to increased GLUT1 and GLUT4 expression, thus allowing more uptake of glucose to fuel glycolysis but also activating (phosphorylates) a number of metabolic enzymes including hexokinase and phosphofructokinase 2, the former of which catalyzes glucose to glucose 6-phosphate, the first step of glycolysis. Additionally, by activating the mammalian target of rapamycin (mTOR), AKT activity leads to increased mRNA translation and protein biogenesis [77] . Another common oncoprotein, Myc, drives aerobic glycolysis directly through the upregulation of glucose transporters and phosphofructokinase-2 [101] and cooperatively with hypoxiainducible factor 1 (HIF-1) to induce hexokinase 2 and pyruvate dehydrogenase [71] . Not surprisingly loss of function of tumor suppressors can mimic the metabolic phenotype driven by oncogene expression. Through the TP53-inducible glycolysis and apoptosis regulator, p53 reduces glycolysis and enhances OXPHOS through SCO2 (cytochrome c oxidase 2) [6, 93] . P53 also maintains expression of PTEN, which is the major regulatory brake on the PI3K/AKT/mTOR pathway [133] . Further, PTEN loss or AKT activation leads to increased glycolysis through depletion of ATP stores [29] . These findings highlight the pleiotropic regulation of metabolism by classical oncogenic and tumor-suppressive signaling networks (Fig. 2) .
Tumor redox
A major component of the tumor microenvironment and a poor predictor of outcome is hypoxia, which occurs from the combination of the enhanced metabolic and replicative states of tumor cells with a compromised vasculature [142, 143] . Through activation of HIF-1, hypoxia acts to reinforce glycolysis, and sustained hypoxia leads to mitochondrial dysfunction [104] . Collectively, this results in an abnormal cellular redox status. Redox, which is the balance of the reduced and oxidized states of a cell, is governed by the levels of reactive oxygen (ROS) and nitrogen species and antioxidant molecules. As a consequence of increased ATP production and macromolecule biogenesis, tumor cells accumulate abnormally high levels of ROS [3, 135, 139] . Through posttranslational modifications, these oxidative molecules contribute to tumor progression by augmenting the activity of oncogenic proteins such as PI3K, mitogen-activated protein kinases, and Src while further inhibiting tumor suppressors such as PTEN and PTP [137] . Further, ROS support the transcription of HIF-1α and GLUT1, thus creating a feed-forward mechanism that enhances the Warburg Effect in tumor cells [5] . Although increased ROS production is usually thought of as protumorigenic, certain thresholds of oxidative damage to proteins and nucleic acids can trigger cell death through apoptosis [13, 136] , thus revealing another potential therapeutic opportunity in the treatment of tumors.
Therapeutic targeting of tumor metabolism
An exciting development in tumor therapy is the exploitation of abnormal tumor metabolism [35] . Metformin is an agonist of AMPK (AMP-activated protein kinase), a finely tuned sensor of the cellular AMP/ATP ratio. At high ratios, AMPK is activated and negatively regulates mTOR, thus reducing protein production and proliferation. Secondarily AMPK activity reduces insulin production and gluconeogenesis [128] . Interestingly, before the mechanism of action of metformin was studied, it was already found to improve insulin sensitivity and reduce blood glucose in diabetics. Today this is the most common drug in the treatment of type 2 diabetes [24] . From decades of diabetic patient data, large meta-analyses were performed showing that those patients on metformin have significantly reduced risk of cancer incidence and cancer-associated death [10, 28] , which has led to clinical trials in several solid tumors, including colorectal, endometrial, prostate, breast, and brain (recently reviewed by Kasznicki et al. [66] ). Whereas mouse tumor models and cell culture experiments show that metformin induces mTOR inhibition, growth arrest, and apoptosis of tumor cells [59, 85] , patient data are quite limited. In breast cancer patients, metformin reduces mTOR transcription and the Ki67 staining proliferative index [47] and also improves treatment response rates [62] . Metformin treatment also reduces the rate of colorectal cancer formation and levels of prostate cancer death [52, 107] . Many ongoing clinical trials will elucidate the efficacy of metformin as a first line of treatment, in combination therapy, and in tumor prevention studies. In addition to metformin, multiple drugs that target various aspects of metabolism are in preclinical and clinical trials [35] .
Because metformin negatively regulates pathways downstream of AKT [46] , which are important in tumor ECM remodeling and mechanosignaling, it is possible that use of this drug may help to reduce tissue fibrosis and thereby temper the malignant effects of a stiffened ECM. Exciting recent data in support of this hypothesis include findings that metformin treatment in heart failure-prone rats reduced perivascular fibrosis and prevented heart failure. Additionally, in a mouse model of cardiac fibrosis, metformin Fig. 2 . Regulation of metabolism in tumor cells. Normal cells use the TCA cycle (OXPHOS) for ATP production, whereas oncogenic signaling drives a glycolytic phenotype in tumor cells. PI3K activates AKT, which stimulates glycolysis by directly regulating glycolytic enzymes and by activating mTOR. mTOR has pleiotropic effects on metabolism, but facilitates the glycolytic phenotype by enhancing HIF-1 activity, which engages a hypoxia-adaptive transcriptional program. HIF-1 induces the expression of glucose transporters (GLUTs), glycolytic enzymes, and PDK1, which blocks the entry of pyruvate into the TCA cycle. The LKB1 tumor suppressor activates AMPK, which opposes the glycolytic phenotype by inhibiting mTOR. Myc cooperates with HIF to induce several genes that encode glycolytic proteins, but also increases mitochondrial metabolism. The tumor suppressor p53 opposes the glycolytic phenotype by suppressing glycolysis through TIGAR, increasing mitochondrial metabolism via SCO2 and supporting expression of PTEN. OCT1 acts in an opposing manner to activate the transcription of genes that drive glycolysis and suppress oxidative phosphorylation. The switch to the PKM2 isoform affects glycolysis by slowing the pyruvate kinase reaction and diverting substrates into alternative biosynthetic and reduced NADPH-generating pathways. TCA, tricarboxylic acid; HIF-1, hypoxia-inducible factor 1; LKB1, liver kinase B1; PDK1, pyruvate dehydrogenase kinase, isozyme 1; AMPK, AMP-activated protein kinase; PKM2, pyruvate kinase M2; TIGAR, TP53-induced glycolysis and apoptosis regulator; MCT, monocarboxylate transporter; PDH, pyruvate dehydrogenase. The dashed lines indicate the shift from TCA to glycolysis under the loss of p53 function. Reprinted from [13] by permission of the publisher. treatment led to reduced levels of TGFβ and activated Smad3, thus decreasing collagen deposition and fibrosis [18, 154] . These studies hint at connections between altered tumor mechanics and metabolism, which are discussed below.
Clinical metabolic imaging techniques
Links between dysfunctional metabolism and malignancy have fostered the development of a number of noninvasive clinically tractable approaches to image tissue metabolism in situ. By delivering radioactively tagged glucose to patients, tumors can be detected by their abnormally high uptake of the metabolite. [ 18 F]Fluorodeoxyglucose (FDG) is taken up through GLUT transporters and phosphorylated by hexokinase. Owing to the lack of a 2 0 -hydroxyl group, this radiolabeled analog of glucose is not metabolized further, allowing for the identification of metabolically active tissue with positron emission tomography (PET) imaging. Clinically, FDG-PET has been used successfully in diagnosis, staging, monitoring response to therapy, and predicting outcome in tumors of the breast, colon, and lung [36, 60] . Clinical histopathology and experimental xenograft studies have shown that FDG uptake is correlated with increased HIF-1α and GLUT expression [1, 64] as well as Ki67 proliferative status [49] .
MRI and magnetic resonance spectroscopy (MRS) allow quantitative analysis of metabolites in a tissue. This technique has been particularly useful in the diagnosis and prognosis of brain tumors [95] . An adaptation of MRS is hyperpolarized 13 C MRS, which allows tracing of the fate of 13 C-radiolabeled metabolites.
Although not yet FDA approved, this technique is safe in patients [98] and has been used in cell culture and mouse models to study glutaminase activity in hepatocellular carcinoma cells [33] and the abnormal metabolism of α-ketoglutarate in IDH1 mutant gliomas [16] . Current advances in this technology and reduction in 13 C reagent costs will probably push this technique into the clinic [75] . Metabolic changes occur early during tumorigenesis; thus advancements in FDG-PET and MRS metabolic imaging have the potential to help diagnose various tumor types at much earlier stages.
Another approach that is useful in the metabolic analysis of archived biopsy tissue is the fluorescence imaging of NADH/NADPH and FAD. These ubiquitous metabolic cofactors, which play key roles in glycolysis, OXPHOS, and ROS scavenging, are autofluorescent and readily imaged because of their relatively high concentrations within the cell. Biochemical means have uncovered changes in the redox state of these molecules in tumor cells during early stages of carcinoma and when tumors progress [130, 144, 156] . In addition to intensity, the fluorescence lifetime imaging (FLIM) of NADPH and FAD serves as a readout of metabolic state, as each of these molecules has a unique FLIM value depending on whether it is free in the cytosol or bound to protein (Fig. 3) . Metabolic imaging of NADPH and FAD by FLIM matches metabolic perturbations in culture, and this technology is able to distinguish basal cell skin sarcomas from surrounding normal skin, as well as glioma from normal brain [8, 22, 34, 83, 146] . FLIM of NADPH and FAD discerns early carcinoma in situ of the mammary gland in mouse [20] , suggesting these approaches may be useful for in situ determinations of early changes associated with aerobic glycolysis. Consistent with this finding, our recent data demonstrate that changes in NADPH fluorescence lifetime values may serve as an early biomarker for biochemical changes in tissue that is deemed morphologically normal by standard pathological assessment. The clinical relevance of these approaches is further highlighted by the finding that metabolic imaging by FLIM corresponds to tamoxifen responsiveness in both breast xenographs and human head and neck squamous cell carcinoma [129, 146] .
A proposed role for tissue mechanics-mediated regulation of tumor cell metabolism and cancer progression
Physical forces influence cellular metabolism
A stiffened ECM is becoming appreciated as a critical component of the tumor microenvironment and data are accumulating to show that mechanics and cell adhesion regulate metabolism. Upon integrinmediated ECM adhesion, cells exhibit a spike of ROS that is necessary for subsequent integrin signaling and Src activation [17] , and quenching of ROS reduces v-Src-driven tumorigenicity and invasion [42] . In addition to adhesion, the compliance of ECM has marked effects on cellular growth and proliferation [106, 138] processes, which demand increased metabolic flux. Interestingly, the EMT, a process heavily implicated in invasion, is favored on stiffer substrates [79, 138] , and mesenchymal cell types exhibit increased aerobic glycolysis through increased Zeb1-induced expression of glucose transporters [92] and Snail-induced methylation of fructose 1,6-bisphosphate [23] . Moreover, stiffness-induced Rac1b facilitates formation of the NADPH oxidase complex, which drives ROS production and enhances the EMT phenotype in breast epithelial cells [79] .
The interplay between physical forces and metabolism is perhaps best understood in endothelial cells. Analogous to the regulation of homeostasis by ECM compliance, physiologic (regular pulsatile or laminar flow) shear stress helps regulate gene expression and redox of endothelial cells; however, under conditions of elevated or irregular (turbulent or oscillatory) shear stress, these cells upregulate Rac1 activity, which fuels ROS production, driving NF-κB activation and facilitating atherosclerosis [140] . Further, irregular shear stress in ischemia leads to PI3K/AKT activation and ROS production in a feedforward mechanism [15] . Clear connections between cell adhesion, mechanical signaling, and metabolism exist; however, more studies are needed to understand the molecular mechanism by which these processes influence one another.
Tissue stiffness regulates metabolism and drives cancer progression: a developing direction
Both altered metabolism and deregulated ECM dynamics clearly act as fundamental drivers of cancer progression. However, emerging evidence suggests that these two characteristic features of cancer may also be interconnected, driving the progression of cancer via a synergistic, cooperative network. The PI3K signaling pathway is central for regulation of glucose metabolism. In fact, activation of the PI3K/AKT pathway renders cells dependent on high levels of glucose flux, a classic biochemical phenomenon of cancer cells [12] . In addition to activation of mTOR-mediated signaling, the PI3K pathway also regulates glucose uptake and utilization. In insulin-independent tissues, PI3K signaling through AKT regulates the expression of glucose transporters, GLUT1 and GLUT4 [73] , via hexokinase, thereby stimulating phosphofructokinase activity and increasing glucose uptake [9, 119] , an action critical for enhanced aerobic glycolysis. However, PI3K activation also occurs in the context of increased matrix stiffness via integrin-mediated activation of FAK and downstream pathways [45, 65, 116, 117, 153] . Thus, regulation of PIP3 by PI3K and subsequent activation of AKT and mTOR represent mechanistic means by which matrix stiffness and increased ECM deposition may influence cellular metabolism, thereby promoting both cell proliferation and survival [106, 151] , as well as facilitating oncogenic transformation and tumor metastasis [84] . Matrix stiffness may also regulate metabolism through effects on p53, as AKT drives p53 degradation via MDM2 [53] . Moreover, p53 is further regulated by reduction of cysteine residues and may become inactivated as the redox balance of the cell shifts [31] .
Matrix stiffness-mediated PI3K activation of AKT is also reinforced through β-catenin and Myc-dependent matrix stiffness-induced expression of miR18a, which inhibits PTEN expression and stimulates cancer progression [96] . Consistent with these findings, knockout of FAK in mammary tumors downregulates the activity of PI3K and AKT while enhancing PTEN expression and disrupting tumor growth and metastasis [114] . Activation of PI3K by growth factors alone has also been shown to be insufficient to induce accumulation of PIP3, and oxidation-mediated inactivation of PTEN is required to increase the concentration of PIP3 sufficiently to trigger downstream signaling events [76] . Thus, oxidation-and stiffness-mediated inactivation of PTEN may work cooperatively to trigger the PIP3 downstream signaling events that drive cancer progression. Evidence also suggests a dynamic relationship between cell attachment to the ECM and metabolic activity regulation. Detachment of mammary epithelial cells from ECM causes an ATP deficiency owing to the loss of glucose transport. However, this deficiency can be rescued via overexpression of ErbB2, which restores glucose uptake through stabilization of the epidermal growth factor receptor and PI3K activation via glucose-stimulated flux through the antioxidant-generating pentose phosphate pathway. Interestingly, ATP deficiency can also be rescued by antioxidant treatment without rescue of glucose uptake, which is dependent on stimulation of fatty acid oxidation, a process inhibited by detachment-induced reactive oxygen species [124] . These findings demonstrate that cell attachment to the ECM directly regulates metabolic activity, providing a means for improving cell survival in the disrupted ECM tumor microenvironment through antioxidant restoration of ATP generation.
Intriguing microarray data generated from culturing normal mouse mammary gland cells in dense versus compliant 3D collagen matrices suggests an enhanced oxidative phosphorylation signature in stiffer environments [115] . Although this may reflect the difference between normal and transformed cells, there is increasing evidence that oxidative phosphorylation is also increased in tumors [131] . Increased oxidative phosphorylation in the context of increased aerobic glycolysis allows cells a robust metabolism that may be necessary for the substantial energy demands of proliferation, migration, and metastasis. Indeed, AKT/mTOR activation of 4EBP1 leads to increased mitochondrial biogenesis [44] and may represent an additional means by which matrix stiffness regulates metabolism through a FAK/PI3K/AKT pathway.
Enhanced ECM deposition, aligned collagen, collagen cross-linking, and fibrosis are all key aspects of breast cancer progression. As described here, not only are there solid data suggesting that ECM stiffness stimulates aberrant cell growth, survival, invasion, and metastasis through modulation of the PI3K/AKT network, but ECM stiffness may also contribute to altered cellular metabolism.
Conclusions and future perspectives
Increased deposition, remodeling, and cross-linking of ECM within the breast, and the resulting increased tensile forces, are characteristic of breast cancer progression and also serve to activate signaling pathways critical for proliferation, survival, invasion, and metastasis. Emerging evidence also shows that some of these same ECM-activated signaling pathways promote aerobic glycolysis and glucose uptake. Here we provide evidence that tissue mechanosignaling activates signaling networks that simultaneously promote breast carcinogenesis and metabolic reprogramming. Both altered ECM dynamics and metabolic reprogramming are critical drivers of cancer aggressiveness. Thus, research focusing on their interconnected feedback loop may be a promising direction for biomarker discovery and drug development.
Emerging clinical data have begun to link stiffer matrices with increased cancer aggressiveness in human patients, emphasizing how matrix stiffness and deregulated mechanosignaling components could provide useful strategies for clinical intervention and to identify novel biomarkers [96] . In basal-like or luminal B samples, breast ECM stiffness and miR-18a expression were found to be significantly higher compared to levels measured in the normal and luminal A tumor biopsies. Owing to this mechanically mediated miR-18a expression profile, PTEN expression was found to be expressed in appreciable quantities in the more differentiated luminal B cancers and normal breast tissue, whereas less differentiated luminal B, basal-like, and HER2 þ tumors showed reduced expression of PTEN, along with higher levels of activated AKT (Fig. 4) . MiR-18a levels also distinguished luminal A from luminal B tumors and predicted clinical outcome in patients with luminal type breast cancer. These findings suggest that macro-level tumor stiffness may parallel future disease aggression, with tumor size, grade, and subtype as independent factors influencing tissue mechanics. Furthermore, ECM stiffness acts as a biophysical parameter that can distinguish luminal A from luminal B tumors, with miR-18a and PTEN presenting as tractable biomarkers. Unfortunately, imaging techniques that characterize tissue stiffness in the clinical setting are severely limited. However, because of the interconnected relationship of metabolism and tissue stiffness, the identification of surrogate metabolic markers for tissue stiffness may serve to accurately monitor cancer progression. Altered metabolism and tissue elastic modulus have typically been identified as independent features of cancer. In fact, activation of PI3K/ AKT, excess metabolic energy, and glycolysis are all associated with poor prognosis in triple-negative breast cancer [72, 109, 120] . Interestingly, these factors seem to influence clinical outcome through similar and overlapping pathways. In response to increased mechanical stiffness, integrin clustering, ERK activation, cytoskeletal remodeling, and Rho GTPase-dependent contractility are engaged and foster the assembly of focal adhesions, which in turn collaborate with G-proteincoupled receptors and transmembrane receptor tyrosine kinases to alter PI3K signaling and downstream AKT signaling. Mutations in the key component PI3K lead to subsequent downstream activation of AKT and predict poor survival and risk of recurrence [43, 100] . Genetic defects in mitochondrial respiration and increase in glycolysis also activate AKT signaling via increases in metabolic potential mediated by NADH, which promotes recruitment of GLUTs to the cell surface and increased glucose uptake and glycolysis [91] . These high glucose levels have also been shown to promote the aggressive behavior of triplenegative breast cancer, including proliferation, activation of oncogenic signaling, apoptosis resistance, and reduced drug efficacy [145] . Interestingly, women at high risk for developing triple-negative breast cancer show altered metabolic state [54] . Random periareolar fineneedle aspiration samples taken from high-risk patients were shown to express high levels of activated proteins representing RTK/AKT/ mTOR, RTK/AKT/ERK, and mitochondrial apoptosis, suggesting that significant metabolic dysfunction exists long before tumors can be detected in these patients. The strong correlation between ECM stiffness and AKT suggests that these high-risk women may also have altered ECM, making them prime candidates for elastography imaging studies. PET imaging is also now being used to determine glucose uptake in these high-risk patients (Fig. 5) . Many of these high-risk patients are also involved in chemotherapy prevention trials that include metformin. It will be interesting to see whether this early state of metabolic dysfunction is reversible and whether early targeting of altered metabolism is an effective preventative strategy. Taken together, these studies highlight the central role of AKT and redox activation in defining the aggressive behavior of triple-negative breast cancer. Given the key role that matrix stiffness plays in regulating PI3K/AKT signaling, these studies also provide evidence for the convergence of mechanosignaling and redox activation in aggressive cancers. Because AKT-network signaling is active in premalignant tissue from women at high risk for breast cancer before the development of an invasive phenotype [55, 111] , this opens the possibility that combination therapies that target both cellular metabolism and tissue stiffness may serve to more effectively halt disease progression.
Altered metabolism and ECM stiffening are two chief components of the tumor microenvironment that have a profound impact on cancer progression (Fig. 6) . Although new evidence suggests that both are intricately linked through their downstream signaling pathways, additional studies will need to be conducted to fully investigate their complex relationship. Nevertheless, this newly developing area of cancer research may provide fresh avenues to pursue for the development of tractable biomarkers and novel cancer therapeutics. 
